The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of febrile neutropenia and myelosuppression in patients receiving FOLFOX/FOLFIRI in gastrointestinal cancer treated with same-day (SD) pegfilgrastim/pegfilgrastim-CBQV (PFG).
 
Basel Shoua
No Relationships to Disclose
 
Mahta Mahmoudieh
No Relationships to Disclose
 
Aaron James Scott
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Exelixis; QED Therapeutics
Research Funding - Exelixis; Five Prime Therapeutics; Genentech; Incyte; Merck
Travel, Accommodations, Expenses - Exelixis; QED Therapeutics
 
Jerrelee Hollings
No Relationships to Disclose
 
Rachna T. Shroff
Consulting or Advisory Role - AstraZeneca; Basilea; Boehringer Ingelheim; Clovis Oncology; Exelixis; Genentech; Incyte; Merck; QED Therapeutics; SERVIER; Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb; Exelixis; Immunovaccine; Merck; Novocure; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen; Taiho Pharmaceutical
 
Ali McBride
Consulting or Advisory Role - EMD Serono; Pfizer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb; Coherus Biosciences; Incyte